Two new anticancer drugs that target the MET gene to treat non-small cell lung cancer have entered the Korean market. The two drugs are Novartis’ ‘Tabrecta (capmatinib)’ and Merck’s ‘Tepmetko (tepotinib)’

The Ministry of Food and Drug Safety approved Tabrecta and Tepmetko together on the 23rd. Both are targeted therapies that target MET mutations and have the same indications. Tabrecta and Tepmetko may both be used to treat locally advanced or metastatic NSCLC harboring MET exon 14 skipping mutations.

Various mutations that induce cancer cell growth occur in NSCLC. Dysregulation in the proto-oncogene MET that is located in the long arm of chromosome 7 is also one of such many mutat